News from intarcia therapeutics, inc. A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Sep 12, 2011, 08:00 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes

Intarcia Therapeutics, Inc. announced today the presentation of three clinical abstracts on ITCA 650 (DUROS® subcutaneous continuous delivery...

Jun 28, 2011, 12:45 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions

Intarcia Therapeutics, Inc. announced  today the presentation of final 48-week results of a phase 2 clinical study of ITCA 650 (DUROS®...

Jan 04, 2011, 15:07 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Therapeutics Executive Chairman Kurt Graves to Present at 29th Annual JP Morgan Healthcare Conference

Intarcia Therapeutics, Inc. today announced that Kurt Graves, Executive Chairman of Intarcia Therapeutics, will present at the 29th Annual JP...

Nov 11, 2010, 16:15 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Therapeutics Executive Chairman, Kurt Graves to Present at Lazard Capital Markets 7th Annual Healthcare Conference

Intarcia Therapeutics. Inc today announced that Kurt Graves, Executive Chairman of Intarcia Therapeutics, will be presenting at the Lazard Capital...

Sep 22, 2010, 11:00 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD

Intarcia Therapeutics, Inc. presented today final results of a 24-week phase 2 clinical study of ITCA 650 (DUROS® continuous subcutaneous...

Sep 16, 2010, 14:00 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Therapeutics Names Kurt Graves Executive Chairman to Advance Strategic Interests and Broaden Commercial Goals

The board of directors of Intarcia Therapeutics, Inc. ("Intarcia," the "Company") today announced the appointment of Kurt Graves as executive...

Jun 28, 2010, 10:30 ET

Intarcia Therapeutics, Inc. Presents Positive ITCA 650 Phase 2 Study Results as a Late-Breaker at the American Diabetes Association 70th Scientific Sessions

Intarcia Therapeutics, Inc. presented today the results of a phase 2 clinical study of ITCA 650 (DUROS® continuous subcutaneous delivery of...

Nov 06, 2009, 09:30 ET





	
	
     - 
     - 
     - 









Home  
Contact Support 

Not Found


The requested url was not found on this server - your browser will now be redirected

If your browser does not redirect, please click HOME to be send to the correct location

Please contact support@newscom.com if you feel you have reached this page in error

Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting

Intarcia Therapeutics, Inc. delivered two presentations today on its ITCA 650 (DUROS® continuous delivery of exenatide) program for the...

Sep 30, 2009, 10:00 ET





	
	
     - 
     - 
     - 









Home  
Contact Support 

Not Found


The requested url was not found on this server - your browser will now be redirected

If your browser does not redirect, please click HOME to be send to the correct location

Please contact support@newscom.com if you feel you have reached this page in error

Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference

Intarcia Therapeutics, Inc. today presented final results from its Phase 1b clinical study of ITCA 650 (DUROS® continuous delivery...

Sep 17, 2009, 07:00 ET





	
	
     - 
     - 
     - 









Home  
Contact Support 

Not Found


The requested url was not found on this server - your browser will now be redirected

If your browser does not redirect, please click HOME to be send to the correct location

Please contact support@newscom.com if you feel you have reached this page in error

Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes

Intarcia Therapeutics, Inc. today announced the start of enrollment for a phase 2 study comparing its proprietary drug candidate ITCA 650...

Jun 08, 2009, 08:44 ET





	
	
     - 
     - 
     - 









Home  
Contact Support 

Not Found


The requested url was not found on this server - your browser will now be redirected

If your browser does not redirect, please click HOME to be send to the correct location

Please contact support@newscom.com if you feel you have reached this page in error

Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions

DUROS(R) continuous delivery of exenatide produces impressive reductions in fasting plasma glucose, HbA1c and body weight during 28-day...

May 27, 2009, 10:46 ET





	
	
     - 
     - 
     - 









Home  
Contact Support 

Not Found


The requested url was not found on this server - your browser will now be redirected

If your browser does not redirect, please click HOME to be send to the correct location

Please contact support@newscom.com if you feel you have reached this page in error

Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions

First clinical study evaluating DUROS(R) continuous delivery of exenatide for the treatment of type 2 diabetes Intarcia Therapeutics, Inc. today...

Apr 24, 2009, 10:00 ET





	
	
     - 
     - 
     - 









Home  
Contact Support 

Not Found


The requested url was not found on this server - your browser will now be redirected

If your browser does not redirect, please click HOME to be send to the correct location

Please contact support@newscom.com if you feel you have reached this page in error

Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes

First study evaluating DUROS(R) continuous delivery of exenatide for the treatment of type 2 diabetes Intarcia Therapeutics, Inc. today announced...

Jun 06, 2007, 01:00 ET





	
	
     - 
     - 
     - 









Home  
Contact Support 

Not Found


The requested url was not found on this server - your browser will now be redirected

If your browser does not redirect, please click HOME to be send to the correct location

Please contact support@newscom.com if you feel you have reached this page in error

FierceBiotech Names Intarcia Therapeutics as One of the 'Fierce 15' Biotech Companies of 2007

EMERYVILLE, Calif., June 6 /PRNewswire/ -- Intarcia Therapeutics, Inc. announced today that it has been named to the annual FierceBiotech...

May 21, 2007, 01:00 ET





	
	
     - 
     - 
     - 









Home  
Contact Support 

Not Found


The requested url was not found on this server - your browser will now be redirected

If your browser does not redirect, please click HOME to be send to the correct location

Please contact support@newscom.com if you feel you have reached this page in error

Intarcia Therapeutics Announces Presentation of Final Results From a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference

WASHINGTON, May 21 /PRNewswire/ -- Intarcia Therapeutics, Inc., a privately held biopharmaceutical company, today announced the presentation of...

Apr 12, 2007, 01:00 ET

Intarcia Therapeutics Announces Final Results From a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1

BARCELONA, Spain, April 12 /PRNewswire/ -- Intarcia Therapeutics, Inc., a privately held biopharmaceutical company, today announced final...

Mar 19, 2007, 01:00 ET





	
	
     - 
     - 
     - 









Home  
Contact Support 

Not Found


The requested url was not found on this server - your browser will now be redirected

If your browser does not redirect, please click HOME to be send to the correct location

Please contact support@newscom.com if you feel you have reached this page in error

Intarcia Raises $50 Million in a Series BB Financing

EMERYVILLE, Calif., March 19 /PRNewswire/ -- Intarcia Therapeutics, Inc., a privately held biopharmaceutical company, announced today the...

Jan 04, 2006, 00:00 ET





	
	
     - 
     - 
     - 









Home  
Contact Support 

Not Found


The requested url was not found on this server - your browser will now be redirected

If your browser does not redirect, please click HOME to be send to the correct location

Please contact support@newscom.com if you feel you have reached this page in error

Intarcia Therapeutics to Present at the 24th Annual JPMorgan Healthcare Conference

SAN FRANCISCO, Jan. 4 /PRNewswire/ -- Intarcia Therapeutics, Inc., a privately held, biopharmaceutical company, today announced that it will...

Sep 21, 2005, 01:00 ET





	
	
     - 
     - 
     - 









Home  
Contact Support 

Not Found


The requested url was not found on this server - your browser will now be redirected

If your browser does not redirect, please click HOME to be send to the correct location

Please contact support@newscom.com if you feel you have reached this page in error

Intarcia Therapeutics Will Withdraw Initial Public Offering

EMERYVILLE, Calif., Sept. 21 /PRNewswire/ -- Intarcia Therapeutics, Inc. announced today that it will be requesting the withdrawal of its...

Feb 25, 2005, 00:00 ET

Intarcia Therapeutics Announces Its Phase 3 Clinical Trial for Advanced Breast Cancer

EMERYVILLE, Calif., Feb. 25 /PRNewswire/ -- Intarcia Therapeutics, Inc., a privately held, biopharmaceutical company, initiated its CAT...